-
The authors assessed the risk of venous thrombosis (vt) in current users of non-oral hormonal contraception using four national registries in Denmark.
-
In this issue: Dementia and benzodiazepines; effectiveness of omega-3 fatty acid and Ginkgo biloba supplements; and FDA actions.
-
Although the incidence of hysterectomy has declined in recent years, it remains the most common major gynecologic procedure, and many women are offered or consider elective bilateral oophorectomy (BSO) at the time of hysterectomy to reduce ovarian cancer risk.
-
Mediators of the autonomic response to stress, such as the catecholamines norepinephrine and epinephrine, promote cancer growth, metastasis, and progression in preclinical models.
-
Between September 1, 1987, and January 31, 2001, a total of 4047 obese persons were enrolled in the Swedish Obesity Study (SOS) intervention trial.
-
The emergence of maternal DNA testing for fetal an-euploidies has necessitated a rethinking of our standard screening protocols. With reasonable accuracy, a single blood test can now rule out fetal trisomy 21, 18, and 13, in addition to sex chromosome abnormalities such as Turner syndrome.
-
-
Emergency contraception (EC) should be widely available and easily accessible to all women, according to a just-released committee opinion issued by the American College of Obstetricians and Gynecologists (ACOG).
-
Public health is a familiar setting for many readers of Contraceptive Technology Update. About 51% of respondents to the 2012 Salary Survey say they work in a health department, and most noted no changes in 2012 staffing numbers.
-
An annual Pap smear might soon become a thing of the past. Most women should be screened for cervical cancer no more often than once every three to five years, according to new cervical cancer screening guidance issued by the American College of Obstetricians and Gynecologists (ACOG).
